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Abstract
Alstro ¨m Syndrome (ALMS) is a rare genetic disorder (483 living cases), characterized by many clinical manifestations,
including blindness, obesity, type 2 diabetes and cardiomyopathy. ALMS is caused by mutations in the ALMS1 gene,
encoding for a large protein with implicated roles in ciliary function, cellular quiescence and intracellular transport. Patients
with ALMS have extensive fibrosis in nearly all tissues resulting in a progressive organ failure which is often the ultimate
cause of death. To focus on the role of ALMS1 mutations in the generation and maintenance of this pathological fibrosis, we
performed gene expression analysis, ultrastructural characterization and functional assays in 4 dermal fibroblast cultures
from ALMS patients. Using a genome-wide gene expression analysis we found alterations in genes belonging to specific
categories (cell cycle, extracellular matrix (ECM) and fibrosis, cellular architecture/motility and apoptosis). ALMS fibroblasts
display cytoskeleton abnormalities and migration impairment, up-regulate the expression and production of collagens and
despite the increase in the cell cycle length are more resistant to apoptosis. Therefore ALMS1-deficient fibroblasts showed a
constitutively activated myofibroblast phenotype even if they do not derive from a fibrotic lesion. Our results support a
genetic basis for the fibrosis observed in ALMS and show that both an excessive ECM production and a failure to eliminate
myofibroblasts are key mechanisms. Furthermore, our findings suggest new roles for ALMS1 in both intra- and extra-cellular
events which are essential not only for the normal cellular function but also for cell-cell and ECM-cell interactions.
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Introduction
Alstro ¨m Syndrome [ALMS (MIM #203800)] is a rare,
autosomal recessive monogenic disease characterized by a wide
spectrum of clinical manifestations involving multiple organs,
including blindness, severe insulin resistance, type 2 diabetes,
obesity and cardiomyopathy that progressively affects multiple
organ systems [1].
Alstro ¨m Syndrome is caused by mutations in ALMS1, a large
.230 kb gene located on chromosome 2p13 with ubiquitous
expression in most tissues affected [2,3]. The ALMS1 protein
localizes to the centrosomes and basal bodies of ciliated cells, and
roles in microtubular organization, intracellular transport, and
cilia assembly or function have been suggested [4,5,6]. RNA
interference knockdown experiments indicate that the total lack of
ALMS1 impairs cilia formation [7], supporting the inclusion of
ALMS in a wide class of human genetic disorders called
‘‘ciliopathies’’ [8].
Pathological observations from post-mortem ALMS specimens
reveal extensive fibrosis in most organs [9]. The fibrotic damage
observed in ALMS patients, most notably in cardiac, pulmonary,
hepatic and renal tissue, appears to strongly influence the patients’
prognosis and is often associated with premature death.
Fibrosis is a complex tissue disease [10,11] in which fibroblasts
are the main cell type involved. During tissue repair and fibrosis,
fibroblasts shift from a quiescent state regulating ECM turnover to
a proliferative and contractile ‘activated’ phenotype (myofibro-
blast) [12], in which they secrete higher ECM levels and several
growth factors and cytokines [11,13]. Removal of activated
fibroblasts seems to be crucial in the resolution of the
fibroproliferative responses and an imbalance between fibroblast
proliferation and apoptosis could lead to pathological scarring or
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model to study fibroblast behavior and mechanisms of patholog-
ical regulation during inflammation and wound healing, in
particular in fibrotic disorders such as keloid formation [15] and
scleroderma [16].
We focused on the role of ALMS1 mutations in the development of
fibrosis using primary cultured fibroblasts of 4 ALMS patients
obtained from derma, a region with no signs of fibrotic lesions. To
determine whether there were motility/cytoskeleton alterations in
ALMS fibroblasts, we characterized morphological features in 2D (bi-
dimensional) and 3D (tri-dimensional) cultures by optical and
electron microscopy. Using gene expression arrays, we found the
modulation of genes related to ‘‘cellcycle’’,‘‘apoptotic pathways’’ and
to ‘‘cellular architecture and motility’’. Altogether, our results show
that ALMS fibroblasts up-regulate collagen expression and secretion,
display a longer cell cycle, and are more resistant to apoptotic stimuli.
Materials and Methods
Subjects
Four patients (PT1–PT4) with typical clinical features of ALMS
(3 males/1 female, age 24–37 years) participated in this study. PT2
and PT3 are brothers. Genetics and clinical characteristics are
reported in Table 1.
Three healthy, normal weight control subjects (C1–C3) (2
females/1 male, age 53–74 years) with no endocrine or metabolic
alterations served as control subjects. We evaluated some
senescence markers (mRNA expression of age-associated genes,
telomere length and senescence associated (SA)- b galactosidase
activity) and showed that control and ALMS fibroblasts were not
influenced by the different age of the donors (Figure S1 and S2.)
Ethics Statement
Each subject gave informed written consent for dermal biopsy
and use of gDNA and cDNA; the Ethical Committee of Padua
Hospital approved the research protocol.
Mutation analysis
cDNA obtained from dermal fibroblasts and gDNA isolated
from peripheral blood samples of ALMS patients were amplified
using a standard PCR protocol with HotStarTaq Master Mix Kit
(QIAGEN GmbH, Hilden, Germany). Primer sequences are
available on request. Amplicons were purified, sequenced using
ABI PRISM Big Dye Terminator Cycle sequencing Ready
Reaction Kits and analyzed by ABI 3100 Sequencing Analyzer
(Applied Biosystems, Carlsband, CA, USA). Sequences were
compared with the unaffected control and the mRNA reference
sequence (NM_015120.4).
Table 1. Genetics and clinical characteristics of four ALMS patients studied.
PT1 PT2 PT3 PT4
q % h e
ALMS1 mutation* c.[8938C.T] c.[3425C.G] c.[3425C.G] c. [2164A.T]
+[8938C.T] +[3425C.G] +[3425C.G] +[11313_11316delTAGA]
(exon 10) (exon 8) (exon 8) (exon 8)+(exon16)
p.Q2980X p.S1142X p.S1142X p.K722X+D3771fsX3790
Age 37 years 36 years 24 years 29 years
Gender female male male male
BMI (kg/m
2) 22,2 27,7 27 34,4
Short stature Yes Yes Yes Yes
Retinopathy Yes Yes Yes Yes
(1 year) (3 months) (3 months) (1 month)
Hearing loss Yes Yes Yes Yes
(19 years) (6 years) (1 year) (10 years)
Type 2 diabetes Yes IGT No Yes
(32 years) (34 years) (27 years)
Dyslipidemia Yes Yes Yes Yes
(25 years) (13 years) (4 months) (10 years)
Cardiomyopathy No No No No
Pneumopathy No No No No
Hepatic disorders** Mild Mild Mild Yes
(25 years) (12 years) (24 years) (10 years)
Nephropathy*** Mild Mild No Yes
(32 years) (35 years) (24 years)
Hypogonadism No Yes Yes Yes
The parameters were measured at the time of dermal biopsies. The age of first diagnosis of disease is reported in parenthesis.
*The nomenclature was established according to den Dunnen et al. [29]; the number of the corresponding exon in which the mutation is localized is reported in
parenthesis.
**Elevation of transaminases or ultrasographic signs of liver steatosis.
***Elevation of Blood Urea Nitrogen or creatinine or abnormal Glomerular Filtration Rate assessed by kidney scintigraphy.
doi:10.1371/journal.pone.0019081.t001
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Bidimensional (2D) cultures. Dermal biopsy was
performed from the glabrous surface of the forearm of ALMS
patients and healthy controls. Fibroblasts were maintained in
DMEM high glucose (HG) medium (Dulbecco’s Modified Eagle
Medium GIBCO, Invitrogen LifeTecnologies, Paisley, UK),
150 U/ml streptomycin, 200 U/ml penicillin, 2 mM glutamine,
1 mM HEPES (GIBCO) (standard medium, SM), containing 10%
FBS (fetal bovine serum) (GIBCO). All experiments described
were performed after cell synchronization achieved by growth to
sub-confluency and checked by flow cytometry analysis of the cell
cycle. Primary cells were used between passages 3 and 14, and
experiments were performed using fibroblast cultures at the same
passage.
Tridimensional (3D) cultures. Fibroblasts were seeded in
scaffolds of HYAFF-11
TM (161 cm) (supplied by Fidia Advanced
Biopolymers, Abano Terme, Italy), at a density of 10
6 cells/cm
2,i n
10% FBS SM.
Histological and morphological analysis
Standard hematoxylin and eosin staining was performed in 2D
and 3D-fibroblasts fixed in formalin and paraffin-embedded
(SIGMA, Sigma Aldrich, St Louis, MO, USA). Cell length was
measured using Leica IM1000 Image Manager software (Leica
Microsystem, Heerbrugg, Switzerland). Cell number was assessed
by cell counting in Bu ¨rker chambers, after staining with 0.2%
trypan blue. Fibroblasts harvested by trypsinization were analysed
on a FACS Calibur flow cytometer (Becton Dickinson Immuno-
cytometry System, San Jose, CA, USA).
The cytochemical staining for (SA)- b galactosidase was
performed as previously described [17]. Briefly, cells seeded at the
density of 10
4 cells/cm
2 were fixed using 3% formaldehyde for
5 minutes. Subsequently, cells were rinsed in PBS and incubated at
37uC for 16 hours with the following staining solution: 1 mg/ml 5-
bromo-4-chloro-3-indolyl-b-D-galactopyranoside, (X-gal) (Merck
KGaA, Whitehouse Station, NJ, USA), 5 mM potassium ferrocy-
anide, 5 mM potassium ferricyanide, 150 mM NaCl, 2 mM
MgCl2 and 40 mM citric acid pH 6.0 (SIGMA). Representative
fields were photographed at 326 magnification using Remote
Capture software (Canon) and the DM IL inverted microscope
(Leica).
3D-cultures were fixed in 2.5% glutaraldehyde in 0.1 M
phosphate buffer pH 7.4 for 3 hours, post-fixed with 1% osmium
tetroxide, dehydrated, and embedded in araldite (SIGMA).
Ultrathin sections were stained with uranyl acetate and lead
citrate, and analyzed with a Philips EM400 electron microscope
(Philips, Eindhoven, The Netherlands).
RNA extraction and DNAse treatment
Total RNA was extracted from 2D cultures with an RNeasy
Mini Kit (QIAGEN GmbH, Hilden, Germany). RNA was
quantified using NanoDrop technology (Fisher Scientific SAS,
Illkirch Cedex, France), quality-checked using an Agilent 2100
Bioanalyzer (Agilent Technologies, PaloAlto, USA) and treated
with DNase Treatment & Removal Reagents (Ambion, Inc,
Austin, TX, USA).
DNA microarray experiments
We used slides spotted by the Microcribi Core Facility at the
University of Padua (http://microcribi.cribi.unipd.it), containing
21329 oligonucleotides from Operons 70 mer oligo collection
(Human Version 2.0) spotted in duplicate (GPL2136136 record in
the GEO database) on MICROMAX glass slides SuperChip I
(Cat No MPS696, PerkinElmer Life Sciences Inc., Boston, MA,
USA).
One DNAse treated total RNA sample (1.5 mg), extracted from
each fibroblast cultures of controls and patients (n=7), was
subjected to linear amplification with SuperScript
TM Indirect
RNA Amplification System (Invitrogen). The resulting aminoallyl
labelled aRNA was coupled with fluorescent dyes Cy3 and Cy5
(CyDye Post Labelling Reactive Dyes, GE Healthcare Life
Sciences, Piscataway, NJ, USA). Each patient’s RNA sample
(PT1, PT2, PT3, PT4) was co-hybridized with a control’s pooled
RNA (C1+C2+C3) and analyzed in replicate with dye swap, for a
total of 8 slides (n=8). 1.5 mg of aRNA labeled with 200 pmoles of
fluorophore were used for each hybridization performing as
previously described [18] with the ArrayBooster
TM (Advalytix,
Brunnthal, Germany) at 48uC for 12 h. The fluorescence was
detected with the ScanArray Lite Scanner and analyzed using
QuantArray Software (PerkinElmer). All data are MIAME
compliant and the raw data have been deposited in a MIAME
compliant database, ArrayExpress database (http://www.ebi.ac.
uk/arrayexpress/), with accession number E-MEXP-2492.
RT-Real time PCR
Two DNAse treated RNA (2 mg) samples, independently
extracted from fibroblast cultures of each subjects (n=14) and
different from the RNA samples used for microarray analysis, were
reverse-transcribed for 1 h at 37uC with 150 ng random
hexamers, 0.5 mM dNTPs, 20 U of RNAsin Ribonuclease
Inhibitor and 200 U of M-MLV (Moloney murine leukemia virus)
Reverse Transcriptase (Promega, Madison, WI, USA). Quantita-
tive PCR was performed using fluorigenic SYBR Green PCR
Master Mix (Invitrogen) on DNA Engine Opticon
TM 2 Contin-
uous Fluorescence Detection System (MJ Research, MA, USA).
Oligonucleotide sequences and reaction conditions are reported in
the Table S1. Each cDNA sample (5 ng) was assayed in duplicate
in at least two independent qPCR reactions (n=56). Results were
normalized with HMBS (hydroxymethylbilane synthase) mRNA
content and reported as arbitrary units ratio.
[
3H]-proline incorporation
2610
4 cells were cultured for 24 h in 10% FBS SM, followed by
24 hours in 0.1% FBS SM. 0.5 mCi/well [
3H]-proline (GE
Healthcare Life Sciences) in 0.1% FBS SM was added and cells
were cultured for the following 72 h. Cells were lysed with 10%
SDS while the culture medium was collected, incubated
30 minutes at 4uC with an equal volume of 20% trichloric acid
(TCA) and centrifugated (13000 g for 15 min) for protein
precipitation. The pellet was washed with 10% TCA and dissolved
in 200 ml 0.3 M NaOH, 0.3% SDS. Radioactivity was quantified
using a b-counter (PerkinElmer) and normalized to DNA content,
estimated by measuring the OD at 260 nm. Each sample was
assessed in duplicate and every experiment was performed at least
3 times.
Cell cycle length estimation and proliferation assay
Fibroblasts were grown in 10% FBS SM to approximately 80%
confluence, and 2.5610
3 cells were plated in 96-well microtiter
plates in 10% FBS SM or in 2% FBS SM. In a second set of
experiments, fibroblasts to approximately 80% confluency were
maintained in serum free condition for 48 hours and then plated
in 96-well microtiter plates in 10% FBS SM at the same density
above reported. At time 0 and after 72 hours cell number was
determined using CellTiter-GloH Luminescent Cell Viability
Assay (Promega) by a Victor3
TM luminometer (PerkinElmer) to
Genetic Basis for Fibrosis in Alstro ¨m Syndrome
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triplicate and analyzed in 3 independent experiments.
Cell viability assay
10
4 cells were plated in 96-well microtiter plates in 10% FBS
SM and treated with 100 nM thapsigargin (THAP), 100 nM
staurosporine (STP) and 100 ng/ml TNF-a for 48 hours, with
100 mg/ml cycloheximide (CX) and 100 mMC 2-ceramide (C2-
C) (SIGMA) for 24 hours. MTT [3-(4,5-dimethylthiazol-2-
yl)2,5-diphenyltetrazolium bromide] solution in PBS was added
to each well (0.4 mg/ml) for 3 hours at 37uC. Medium was
removed and the formazan precipitate was dissolved in
dimethylsulfoxide (SIGMA). OD was measured at 550 nm with
a reference at 620 nm, using a Victor3
TM spectrometer
(PerkinElmer). Cell viability was calculated as a percentage of
absorbance in comparison with untreated cells. Each sample
Figure 1. Size, shape and ultrastructural evaluation of ALMS fibroblasts. (a) Fibroblasts of healthy control (C3) and (b) ALMS patient (PT3)
were grown on standard tissue culture (2D cultures) coverslips and stained with hematoxylin-eosin (magnification 206). (c) Cell length of about 40
fibroblasts per subject was quantified by measuring the longitudinal cell length and was plotted as mean (horizontal line), maximal and minimal
length values (vertical line). **P,0.01 ALMS fibroblast length mean versus controls length mean. (d) The area covered by fibroblast cells during
exponential growth was estimated by cell counting in Bu ¨rker chambers, after 0.2% trypan blue staining. Results are reported as mean 6 SEM.
*P,0.05. ALMS fibroblasts were compared with controls by flow cytometric analysis: (e) the resulting forward (FSC) and (f) side light scatter (SSC)
mean intensity values are shown for each subject. Controls: C1, black triangle; C2, black star; C3, black diamond; Patients: PT1, white circle; PT2, white
square; PT3, white triangle; PT4, white diamond (see also Table 1). Panel g reports the SSC distribution of fibroblasts from C1 (black line) and PT1 (grey
line) showing the highly significant shift (***P,0.001, as determined by the Kolmogorov-Smirnov analysis according to the Macintosh CELLQuest
software user’s guide, Becton Dickinson). (h) Fibroblasts of healthy control (C2) and (i) ALMS patient (PT2) were cultured in HYAFF-11
TM scaffolds (3D-
cultures) and stained with hematoxylin-eosin (magnification 56; * biomaterial scaffolds; R fibroblast cells). Transmission electron microscopy was
performed in healthy control (C2) (l–n–p) and ALMS patient (PT2) (m–o–q) on 3D-cultured cells. Control fibroblasts showed a normal phenotype, with
typical bipolar morphology (l), cytoplasm rich in perpendicular oriented microfilaments (n, ring), the presence of normal pinocytic vesicles (l arrow
and p) and probably collagen fibers in the extracellular space (p, ring). In contrast, ALMS fibroblasts appeared as elongated cells tightly adherent to
each other and showed well-defined long cytoplasmic extensions (m). Microfilaments (o, ring) were arranged in a unique direction, parallel to the
long axis of the cells. A large amount of exocytic vesicles and probably collagen fibrils (q, arrow and ring, respectively) suggest active secretion.
Magnification: l–m=50006; n–o=250006; p=400006; q=300006(see also Figure S3 and S4).
doi:10.1371/journal.pone.0019081.g001
Genetic Basis for Fibrosis in Alstro ¨m Syndrome
PLoS ONE | www.plosone.org 4 April 2011 | Volume 6 | Issue 4 | e19081was assessed in triplicate and each experiment was performed at
least 3 times.
Cell cycle analysis
1610
6 cells were washed with PBS, fixed with 70% (v/v) cold
ethanol for 30 minutes at 4uC, centrifuged (300 g for 8 min) and
washed in PBS. Cells were stained with Propidium Iodide (PI)
(50 mg/ml), in the presence of RNAse A (0.5 mg/ml) (SIGMA) at
4uC in the dark for 30 minutes. DNA content was analyzed on a
FACS Calibur flow cytometer (Becton Dickinson Immunocyto-
metry System).
Detection of apoptosis by DNA end-labeling (TUNEL)
DNA fragmentation was measured using the DeadEnd
TM
Fluorimentric TUNEL System (Promega). Fibroblasts were
plated on coverslips at 2610
4 cells/cm
2, and upon treatment
fixed in 4% paraformaldehyde solution in PBS and permeabilized
in 0.2% Triton X-100 in PBS at r.t. for 5 minutes. DNA was
labeled with fluorescein-12-dUTP by using terminal deoxynu-
cleotidyl transferase enzyme (rTdT) for 1 hour at 37uCi n
humidified chamber. The reaction was terminated in 300 mM
sodium chloride, 30 mM sodium citrate buffer at r.t. for
15 minutes. Nuclei were counter-stained with 4,6-diamidino-2-
phenylindole (DAPI, VectashieldH, Vector Laboratories, Burlin-
game, CA, USA). Coverslips were observed under a Leica
fluorescence microscope (Leica DM LB2, Leica Microsystem).
Alternatively, fibroblasts upon treatment were harvested with
25% trypsin (v/v) and 2610
6 cells were fixed in 1% paraformal-
dehyde solution in PBS for 20 minutes at 4uC and permeabilized
in 70% (v/v) cold ethanol at 220uC for 4 hours. DNA was
labeled as previously described and the labeling reaction was
terminated by the addition of 20 mM EDTA. Cells were stained
in the dark with PI (50 mg/ml), in the presence of RNAse A
(0.5 mg/ml) (SIGMA) at 4uC for 30 minutes, and analyzed on a
FACS Calibur flow cytometer (Becton Dickinson Immunocyto-
metry System).
Telomere length measurement by quantitative Real time
PCR
DNA was extracted by the standard phenol/chloroform method
from fibroblasts cells. Telomere length was quantified as previously
described [19].
Statistics and microarray data analysis
Results are reported as mean value 6 standard error (SEM).
Statistical comparison between two sets of data was performed
using unpaired Student’s t test (two-tailed) or unpaired Mann
Whitney test (two-tailed) in respect to the distribution and size of
samples. Differences were considered significant at P,0.05.
Low intensity spots of microarray were removed from both
channels applying Z-score transformation and we balanced raw
intensities applying LOWESS (locally weighted scatter plot
smoothing), discarding outlier values from the analysis for every
slide. For each slide, we removed incongruent replicates
calculating the ratio between ch1 and ch2 intensity for the 2
replicate with dye swap (respectively R1 and R2) and the standard
deviation (SD). After that, we calculated the log2(R1/R2) and
excluded the spots showing the value higher than 3SD. We
considered only the genes that have the same expression pattern in
all patients analyzed. Subsequently, we calculated the geometric
means for the filtered genes and applied one class SAM
(Significance Analysis of Microarrays) analysis to identify the
differentially expressed genes by grading each gene using a
modified t test [20]. For each gene SAM software calculates a false
discovery rate (FDR) which is an estimation of the percentage of
genes identified as differentially expressed by chance. In our
analysis only the genes with 0% FDR were included in the
subsequent analysis. To analyze the biological meaning of the
selected genes we used GoMiner software (Gene Ontology, http://
www.geneontology.org/) and the KEGG database (Kyoto Ency-
clopedia of Gene and Genome, http://www.genome.jp/kegg/).
To avoid the loss of information regarding differentially expressed
genes we performed also a careful analysis of published literature
and we will refer to this as ‘‘gene by gene’’ approach.
Results
Size, shape and ultrastructural evaluation of ALMS
fibroblasts
ALMS cells (PT1–PT4) are more elongated, with well defined
cytoplasmic extensions, compared to controls (C1–C3)
(Figure 1a,b,c) and occupied a larger surface than healthy cells
(Figure 1d). Nevertheless in suspension ALMS and control
fibroblasts displayed similar dimensions (Figure 1e), whereas two
of the mutated ones possessed a major cellular complexity
(Figure 1f,g and Figure S3).
Figure 2. Distribution of differentially expressed genes in ALMS fibroblasts. Fibroblast transcriptional profiles were analyzed by whole
genome expression experiments using RNA isolated from healthy controls and ALMS fibroblasts. (a) Pie chart shows the percentage of differentially
expressed genes (n=560) in ALMS fibroblasts clustered in main categories: cell cycle (n=90), ECM components/fibrosis regulation (n=37), cellular
adhesion/motility (n=24) and apoptosis (n=18). (b) Bar chart displays the distribution of up- (black) and down- (grey) regulated genes for each
identified group with the number of corresponding genes. A detailed description of the whole genome expression analysis is given in Table S2.
doi:10.1371/journal.pone.0019081.g002
Genetic Basis for Fibrosis in Alstro ¨m Syndrome
PLoS ONE | www.plosone.org 5 April 2011 | Volume 6 | Issue 4 | e19081T
a
b
l
e
2
.
G
e
n
e
O
n
t
o
l
o
g
y
d
i
s
t
r
i
b
u
t
i
o
n
o
f
d
i
f
f
e
r
e
n
t
i
a
l
l
y
e
x
p
r
e
s
s
e
d
g
e
n
e
s
i
n
m
i
c
r
o
a
r
r
a
y
a
n
a
l
y
s
i
s
.
B
I
O
L
O
G
I
C
A
L
P
R
O
C
E
S
S
G
O
I
D
C
h
a
n
g
e
d
/
T
o
t
a
l
g
e
n
e
s
P
-
V
a
l
u
e
C
h
a
n
g
e
d
g
e
n
e
s
C
E
L
L
U
L
A
R
C
O
M
P
O
N
E
N
T
G
O
I
D
C
h
a
n
g
e
d
/
T
o
t
a
l
g
e
n
e
s
P
-
V
a
l
u
e
C
h
a
n
g
e
d
g
e
n
e
s
M
O
L
E
C
U
L
A
R
F
U
N
C
T
I
O
N
G
O
I
D
C
h
a
n
g
e
d
/
T
o
t
a
l
g
e
n
e
s
P
-
V
a
l
u
e
C
h
a
n
g
e
d
g
e
n
e
s
C
e
l
l
c
y
c
l
e
7
0
4
9
5
3
/
5
3
9
0
C
o
l
l
a
g
e
n
5
5
8
1
9
/
3
0
0
G
r
o
w
t
h
f
a
c
t
o
r
b
i
n
d
i
n
g
5
5
2
0
1
0
/
1
9
0
7
5
9
/
3
5
0
5
5
8
3
6
/
1
0
0
1
9
8
3
8
1
2
/
5
0
0
8
7
2
4
/
1
1
6
0
5
5
8
8
2
/
3
0
.
0
0
7
2
B
i
n
d
i
n
g
t
o
e
x
t
r
a
c
e
l
l
u
l
a
r
m
a
t
r
i
x
c
o
n
s
t
i
t
u
e
n
t
5
5
4
0
4
/
1
1
0
.
0
0
1
5
2
7
8
2
8
/
1
5
7
0
5
5
9
8
1
/
1
0
.
0
4
9
8
5
5
1
8
4
/
1
4
0
.
0
0
4
1
2
7
9
2
7
/
1
4
7
0
5
5
9
5
1
/
1
0
.
0
4
9
8
5
5
2
1
9
/
7
2
0
.
0
0
7
2
7
0
6
7
2
4
/
1
1
4
0
5
5
9
1
1
/
1
0
.
0
4
9
8
5
5
3
9
9
/
7
2
0
.
0
0
9
5
1
3
0
1
1
8
/
1
2
6
0
5
5
8
6
1
/
1
0
.
0
4
9
8
3
0
2
4
7
9
/
7
3
0
.
0
0
9
9
7
0
8
8
8
/
3
3
0
.
0
0
0
2
5
5
8
2
1
/
1
0
.
0
4
9
8
1
8
7
1
9
/
7
6
0
.
0
1
2
7
7
0
9
3
5
/
1
2
0
.
0
0
0
2
M
i
c
r
o
f
i
b
r
i
l
1
5
2
7
3
/
3
0
.
0
0
0
1
E
x
t
r
a
c
e
l
l
u
l
a
r
m
a
t
r
i
x
c
o
n
s
t
i
t
u
e
n
t
5
2
0
1
1
0
/
6
9
0
.
0
0
2
7
4
3
2
/
3
7
0
0
.
0
0
1
5
F
i
b
r
i
l
4
3
2
0
5
3
/
4
0
.
0
0
0
5
D
N
A
d
e
p
e
n
d
e
n
t
A
T
P
a
s
e
a
c
t
i
v
i
t
y
8
0
9
4
6
/
2
8
0
.
0
0
2
2
5
1
7
2
6
3
2
/
3
7
0
0
.
0
0
1
5
E
x
t
r
a
c
e
l
l
u
l
a
r
m
a
t
r
i
x
5
5
7
8
2
6
/
3
0
8
0
.
0
0
5
7
D
N
A
p
r
i
m
a
s
e
a
c
t
i
v
i
t
y
9
0
0
8
2
/
6
0
.
0
3
2
4
5
1
3
2
5
8
/
5
4
0
.
0
0
4
9
3
1
0
1
2
2
6
/
3
0
9
0
.
0
0
5
9
D
N
A
-
m
e
t
h
y
l
t
r
a
n
s
f
e
r
a
s
e
a
c
t
i
v
i
t
y
3
8
8
6
2
/
5
0
.
0
2
2
3
5
1
3
2
9
8
/
5
4
0
.
0
0
4
9
D
N
A
p
o
l
y
m
e
r
a
s
e
c
o
m
p
l
e
x
5
6
6
0
4
/
4
0
s
s
D
N
A
b
i
n
d
i
n
g
3
6
9
7
4
/
2
5
0
.
0
3
3
3
8
2
4
/
1
9
0
.
0
1
2
9
5
6
5
9
4
/
5
0
D
N
A
p
o
l
y
m
e
r
a
s
e
a
c
t
i
v
i
t
y
3
8
8
7
4
/
2
7
0
.
0
4
2
8
7
0
9
4
2
/
4
0
.
0
1
3
9
5
6
5
8
3
/
3
0
.
0
0
0
1
3
0
3
3
7
1
/
1
0
.
0
4
9
8
1
6
0
4
3
6
2
/
9
7
5
0
.
0
2
3
8
4
2
5
7
5
4
/
7
0
.
0
0
0
2
R
R
a
c
t
i
v
i
t
y
4
7
4
8
2
/
4
0
.
0
1
3
9
8
2
8
3
3
2
/
4
4
9
0
.
0
2
4
8
5
6
6
2
2
/
3
0
.
0
0
7
2
N
u
c
l
e
o
t
i
d
y
l
t
r
a
n
s
f
e
r
a
s
e
a
c
t
i
v
i
t
y
1
6
7
7
9
8
/
8
0
0
.
0
4
4
7
7
3
4
6
3
/
1
6
0
.
0
4
2
2
5
6
6
3
2
/
4
0
.
0
1
3
9
A
d
e
n
o
s
i
n
e
d
e
a
m
i
n
a
s
e
a
c
t
i
v
i
t
y
4
0
0
0
2
/
4
0
.
0
1
3
9
7
0
8
9
2
/
7
0
.
0
4
3
9
R
e
p
l
i
s
o
m
e
3
0
8
9
4
9
/
1
2
0
M
i
c
r
o
t
u
b
u
l
e
m
o
t
o
r
a
c
t
i
v
i
t
y
3
7
7
7
5
/
3
0
0
.
0
1
5
2
7
0
6
4
1
/
1
0
.
0
4
9
8
5
6
5
7
9
/
1
4
0
M
o
t
o
r
a
c
t
i
v
i
t
y
3
7
7
4
8
/
7
8
0
.
0
3
9
3
7
0
9
5
1
/
1
0
.
0
4
9
8
4
3
6
0
1
9
/
1
2
0
R
e
g
u
l
a
t
i
o
n
o
f
c
e
l
l
g
r
o
w
t
h
1
5
5
8
1
4
/
8
7
0
.
0
0
0
1
4
3
5
9
6
9
/
1
2
0
4
0
0
0
8
1
4
/
9
3
0
.
0
0
0
2
R
R
c
o
m
p
l
e
x
5
9
7
1
1
/
1
0
.
0
4
9
8
1
6
0
4
9
1
5
/
1
1
0
0
.
0
0
0
3
N
u
c
l
e
a
r
c
h
r
o
m
o
s
o
m
e
2
2
8
1
3
/
5
0
0
R
e
g
u
l
a
t
i
o
n
o
f
c
d
k
a
c
t
i
v
i
t
y
7
9
7
/
3
2
0
.
0
0
0
8
5
6
9
4
2
7
/
1
5
7
0
S
p
i
n
d
l
e
o
r
g
a
n
i
z
a
t
i
o
n
a
n
d
b
i
o
g
e
n
e
s
i
s
7
0
5
1
9
/
1
7
0
7
9
4
4
/
1
5
0
.
0
0
5
3
7
0
5
2
5
/
1
1
0
.
0
0
0
1
7
9
3
4
/
2
0
0
.
0
1
5
5
3
1
5
7
7
2
/
4
0
.
0
1
3
9
C
h
r
o
m
o
s
o
m
e
r
e
g
i
o
n
7
7
5
7
/
2
2
0
.
0
0
0
1
2
1
2
1
/
1
0
.
0
4
9
8
C
o
h
e
s
i
n
c
o
r
e
h
e
t
e
r
o
d
i
m
e
r
8
2
8
0
1
/
1
0
.
0
4
9
8
D
N
A
r
e
p
l
i
c
a
t
i
o
n
6
2
6
0
2
7
/
1
3
1
0
K
i
n
e
t
o
c
h
o
r
e
7
7
6
6
/
1
5
0
7
0
4
9
5
3
/
5
3
9
0
S
p
i
n
d
l
e
5
8
1
9
7
/
2
4
0
.
0
0
0
1
6
2
7
0
5
/
1
6
0
.
0
0
0
8
5
8
1
6
2
/
3
0
.
0
0
7
2
6
2
6
9
2
/
3
0
.
0
0
7
2
M
i
c
r
o
t
u
b
u
l
e
c
y
t
o
s
k
e
l
e
t
o
n
1
5
6
3
0
1
4
/
1
4
0
0
.
0
0
9
7
Genetic Basis for Fibrosis in Alstro ¨m Syndrome
PLoS ONE | www.plosone.org 6 April 2011 | Volume 6 | Issue 4 | e19081B
I
O
L
O
G
I
C
A
L
P
R
O
C
E
S
S
G
O
I
D
C
h
a
n
g
e
d
/
T
o
t
a
l
g
e
n
e
s
P
-
V
a
l
u
e
C
h
a
n
g
e
d
g
e
n
e
s
C
E
L
L
U
L
A
R
C
O
M
P
O
N
E
N
T
G
O
I
D
C
h
a
n
g
e
d
/
T
o
t
a
l
g
e
n
e
s
P
-
V
a
l
u
e
C
h
a
n
g
e
d
g
e
n
e
s
M
O
L
E
C
U
L
A
R
F
U
N
C
T
I
O
N
G
O
I
D
C
h
a
n
g
e
d
/
T
o
t
a
l
g
e
n
e
s
P
-
V
a
l
u
e
C
h
a
n
g
e
d
g
e
n
e
s
6
2
7
3
2
/
3
0
.
0
0
7
2
P
o
l
a
r
m
i
c
r
o
t
u
b
u
l
e
5
8
2
7
1
/
1
0
.
0
4
9
8
6
2
7
5
3
/
1
0
0
.
0
1
1
3
C
o
n
t
r
a
c
t
i
l
e
r
i
n
g
5
8
2
6
1
/
1
0
.
0
4
9
8
8
1
5
6
2
/
4
0
.
0
1
3
9
I
n
t
e
r
m
e
d
i
a
t
e
f
i
l
a
m
e
n
t
4
5
1
1
1
8
/
6
1
0
.
0
1
0
2
D
N
A
m
e
t
a
b
o
l
i
s
m
6
2
5
9
4
7
/
3
9
2
0
C
y
t
o
s
k
e
l
e
t
o
n
5
8
8
2
8
/
6
1
0
.
0
1
0
2
5
1
0
5
2
6
/
2
3
0
.
0
0
0
7
K
i
n
e
s
i
n
c
o
m
p
l
e
x
5
8
7
1
3
/
1
1
0
.
0
1
5
5
1
0
5
3
3
/
5
0
.
0
0
1
1
N
u
c
l
e
u
s
t
r
a
n
s
l
a
t
i
o
n
i
n
i
t
i
a
t
i
o
n
f
a
c
t
o
r
2
B
c
o
m
p
l
e
x
5
6
3
4
1
2
7
/
2
2
0
2
0
.
0
2
8
5
D
e
o
x
y
r
i
b
o
n
u
c
l
e
o
t
i
d
e
b
i
o
s
y
n
t
h
e
s
i
s
a
n
d
m
e
t
a
b
o
l
i
s
m
9
2
2
1
2
/
2
0
.
0
0
2
5
5
6
3
5
7
/
6
6
0
.
0
4
4
7
9
2
6
3
2
/
3
0
.
0
0
7
2
5
8
5
1
1
/
1
0
.
0
4
9
8
9
1
8
6
2
/
4
0
.
0
1
3
9
9
2
1
9
2
/
4
0
.
0
1
3
9
9
1
3
2
2
/
6
0
.
0
3
2
4
6
2
2
1
3
/
1
6
0
.
0
4
2
2
9
1
2
4
3
/
1
7
0
.
0
4
9
5
9
1
2
3
3
/
1
7
0
.
0
4
9
5
6
2
3
1
1
/
1
0
.
0
4
9
8
6
2
3
3
1
/
1
0
.
0
4
9
8
6
2
3
5
1
/
1
0
.
0
4
9
8
9
1
3
9
1
/
1
0
.
0
4
9
8
M
i
c
r
o
t
u
b
u
l
e
c
y
t
o
s
k
e
l
e
t
o
n
o
r
g
a
n
i
z
a
t
i
o
n
a
n
d
b
i
o
g
e
n
e
s
i
s
2
2
6
9
/
3
6
0
7
0
1
7
1
3
/
7
7
0
.
0
0
0
1
7
0
1
8
5
/
3
8
0
.
0
3
8
7
7
2
1
/
1
0
.
0
4
9
8
W
e
g
r
o
u
p
e
d
t
h
e
i
d
e
n
t
i
f
i
e
d
t
e
r
m
s
w
i
t
h
t
h
e
c
o
r
r
e
s
p
o
n
d
i
n
g
a
c
c
e
s
s
i
o
n
n
u
m
b
e
r
s
(
G
O
I
D
)
i
n
t
h
e
3
m
a
i
n
O
n
t
o
l
o
g
i
e
s
(
B
i
o
l
o
g
i
c
a
l
P
r
o
c
e
s
s
,
C
e
l
l
u
l
a
r
C
o
m
p
o
n
e
n
t
a
n
d
M
o
l
e
c
u
l
a
r
F
u
n
c
t
i
o
n
)
.
F
o
r
e
a
c
h
G
O
I
D
w
e
r
e
p
o
r
t
e
d
t
h
e
n
u
m
b
e
r
o
f
c
h
a
n
g
e
d
g
e
n
e
s
i
n
o
u
r
e
x
p
e
r
i
m
e
n
t
s
o
u
t
o
f
t
h
e
t
o
t
a
l
g
e
n
e
s
r
e
p
r
e
s
e
n
t
e
d
f
o
r
t
h
a
t
c
l
a
s
s
i
n
t
h
e
a
r
r
a
y
.
F
o
r
e
a
c
h
t
e
r
m
w
e
r
e
p
o
r
t
e
d
a
l
s
o
t
h
e
s
t
a
t
i
s
t
i
c
s
i
g
n
i
f
i
c
a
n
c
e
v
a
l
u
e
s
d
e
r
i
v
e
d
f
r
o
m
G
o
M
i
n
e
r
a
n
a
l
y
s
i
s
(
p
,
0
.
0
5
)
.
d
o
i
:
1
0
.
1
3
7
1
/
j
o
u
r
n
a
l
.
p
o
n
e
.
0
0
1
9
0
8
1
.
t
0
0
2
T
a
b
l
e
2
.
C
o
n
t
.
Genetic Basis for Fibrosis in Alstro ¨m Syndrome
PLoS ONE | www.plosone.org 7 April 2011 | Volume 6 | Issue 4 | e190813D cultures of control fibroblasts showed normal growth inside
the scaffolds (Figure 1h), whereas ALMS fibroblasts did not
penetrate into the biomaterial, with unaffected vitality, giving rise
to a pluri-stratification of cells in the upper side of the biomaterials
(Figure 1i and Figure S4).
Transmission electron microscopy (TEM) analysis confirmed
the normal morphology of control fibroblasts, appearing typically
bipolar, occasionally tripolar (Figure 1l) with an ovoid nucleus and
two to five nucleoli. The cytoplasm presented both rough and
smooth reticulum, numerous mitochondria and occasional
lysosomes. The submembranous cytoplasm was also rich in
microfilaments found in perpendicular arrangement with the
nuclei (Figure 1n). Normal secretion was indicated by the presence
of pinocytic vesicles in the plasma membrane (Figure 1p). In
contrast, ALMS fibroblasts showed elongated nuclei and the
presence of well defined cytoplasmic extensions, strongly anchored
in the extracellular area between adjacent cells (Figure 1m). The
cytoplasm of ALMS fibroblasts was enriched with numerous
mitochondria and lysosomes, and contained microfilaments
arranged in a unique direction parallel to the nuclei (Figure 1o).
An active secretion was suggested by the presence of a large
number of exocytic vesicles (Figure 1q and Figure S4).
Differentially expressed genes in ALMS fibroblasts
We performed whole genome expression analysis comparing
cultured fibroblasts from ALMS patients and healthy controls. Of
about 21500 genes, 560 were scored as differentially expressed,
188 of which were up-regulated whereas 372 were down-regulated
in ALMS patients. We were able to classify differentially expressed
genes in ALMS fibroblasts into 4 groups: cell cycle, extracellular
matrix components/fibrosis regulation, cellular adhesion/motility
and apoptosis (Figure 2, Table 2 and Table S2).
Figure 3. Increased mRNA expression and deposition of ECM components in ALMS fibroblasts. (a) POSTN, ACTA2, COL1A1, COL3A1,
COL4A1, COL5A1, COL5A2, COL8A1, COL11A1, COL12A1, COL15A1 transcripts were quantified by qPCR and normalized to HMBS mRNA content in
control (CONTROLS) and ALMS fibroblasts (ALMS). Results are reported as mean values 6 SEM and are expressed as fold change with respect to
controls, arbitrarily set as 1 for each of analyzed transcript. *P,0.05, ** P,0.01, *** P,0.001 ALMS fibroblasts versus controls (see also Figure S6). (b)
The fold change observed between ALMS and control fibroblasts in microarray analysis was plotted against the fold change measured by qPCR for
ACTA2 and COLs transcript. A strong correlation between the two methods was observed. Pearson coefficient=0.8. (c) Fibroblast collagen protein
synthesis and release were determined by [
3H]-proline incorporation, and expressed as counts per minute normalized to DNA content. *P,0.05,
***P,0.001 ALMS fibroblasts versus controls. Black bars correspond to control and white bars to ALMS fibroblasts.
doi:10.1371/journal.pone.0019081.g003
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PLoS ONE | www.plosone.org 8 April 2011 | Volume 6 | Issue 4 | e19081We observed a down regulation of genes coding for proteins
directly involved in cell cycle progression (several cyclins and
cyclin dependent kinases), in replication, in centrosome-kinetocore
assembly and function, and of genes involved in DNA duplication
as those required in the minichromosome maintenance complex
(MCM) and in the assembly of the replication complex (RFC3-5).
Microarray data showed a strong up-regulation of genes coding
for extracellular matrix components and their regulators in ALMS
fibroblasts, as several collagen types and proteins involved in the
collagen chain assembly [P4HA1 (prolyl 4-hydroxylase, alpha
polypeptide I), LEPRE1 (leucine proline-enriched proteoglycan1)
and SERPINH1 (serpin peptidase inhibitor, clade H, member 1)].
We also found an up-regulation of genes involved in focal
adhesion structures [like TNS1 (tensin1) and LIMS2 (LIM and
senescent cell antigen-like domains2)] and the dystrophin-glyco-
protein complex [SGCD (sarcoglycan, delta)], which are usually
implicated in the regulation of cytoskeleton-ECM interaction.
We found an increase of mRNA for genes which are directly
associated with fibrosis such as POSTN (periostin, osteoblast specific
factor), IGFBP3 and IGFBP5 (insulin-like growth factor binding
protein 3 and 5) and the modulation of 4 members of the CCN
family [enhanced expression of CTGF (connective tissue growth
factor), WISP1 (WNT1 inducible signaling pathway protein 1) and
CYR61 (cysteine-rich, angiogenic inducer, 61) associated with a
down-regulation of NOV (nephroblastoma overexpressed gene),
recently proposed as inhibitor of the fibrotic process]. Finally, we
identified the up-regulation of ACTA2 (actin, alpha2, smooth
muscle, aorta) also known as a-SMA (alpha smooth muscle actin), a
well established marker for myofibroblast conversion. Although
GoMiner software identified only 3 apoptosis related genes [IL24
(interleukin 24), GULP1 (GULP, engulfment adaptor PTB domain
containing1),NALP1(NLRfamily,pyrindomaincontaining1)],the
‘‘gene by gene’’ approach highlighted the modulation of other 15
transcripts [for example POST, EDIL3 (EGF-like repeats and
discoidin I-like domains 3) and MEF2C (myocyte enhancer factor
2C)] engaged in the control of stress-induced cell death.
Increased mRNA expression and deposition of ECM
components in ALMS fibroblasts
We quantified several fibrosis-related genes in an independent
set of cultured fibroblasts by qRT-PCR (Figure S5). As shown in
Figure 3a, the expression levels of all analyzed genes (POSTN,
ACTA2, collagens) were higher in ALMS than in control
fibroblasts (from 1.5 to 151 fold increase) with a highly significant
correlation between microarray data and qPCR determinations
(Figure 3b) (Pearson coefficient=0.8) (see also Figure S6).
Collagen production showed a significant 2–fold increase in
ALMS fibroblasts compared to controls, as assessed by measuring
the [
3H]-proline incorporation into proteins of cellular lysate
(production) and of culture medium (secretion) (Figure 3c).
Moreover TGF-b treatment led to a significant induction type I
collagen (COL1A1) mRNA gene expression, more pronounced in
ALMS fibroblasts than in controls (Figure S7).
ALMS fibroblasts had a longer cell cycle than controls
We analyzed the cell cycle length of fibroblasts grown under
different culture conditions, during the exponential phase of cell
proliferation (Figure 4). Three out of four ALMS fibroblasts
proliferated at a slower rate in comparison with control fibroblasts
in the growth conditions analyzed: normal serum (10% serum),
low serum (2% serum) and serum deprivation (48 hours of serum
deprivation followed by 10% serum).
Three out of four ALMS fibroblasts were more susceptible to a
reduction in cell proliferation rate in response to different culture
conditions (low serum or normal serum upon serum starvation),
resulting in far slower cell proliferation than controls.
ALMS fibroblasts were resistant to cell death induced by
apoptotic stimuli
Figure 5a showed that the % of viable cells in ALMS fibroblasts
was higher than in controls when apoptosis was stimulated with
thapsigargin (THAP), C2-ceramide (C2-C) and cycloheximide
(CX). Staurosporine (STP) treatment, however, led to an equal cell
death in both patient and control fibroblasts, whereas the survival
was not influenced by TNF-a (tumor necrosis factor alpha)
stimulation (see also Figure S8).
To determine whether cell death occurred by apoptosis, we
measured DNA content by FACS (fluorescence activated cell sorting)
analysis upon propidium iodide (PI) staining in two control and two
ALMS fibroblast cultures. The sub-G1/G0 population, which
represents the cells with hypodiploid DNA content in the histogram
(M1 region), increased to 11.4% in control fibroblasts, whereas it did
not change in ALMS fibroblasts after THAP treatment (Figure 5b
and Figure S9). ALMS fibroblasts did not display TUNEL-positive
nuclei upon CX and THAP treatment unlike controls (Figure 5c and
Figure S10). These results were confirmed and quantified by FACS
analysis of apoptotic nuclei of two control and two ALMS fibroblasts
showed in Figure 5d and Figure S9.
Discussion
Severe systemic fibrosis is an universal observation in postmor-
tem and biopsy specimens of ALMS patients and may result in
Figure 4. ALMS fibroblasts display a longer cell cycle than
controls. Cell cycle length of control (C1–C3) and ALMS fibroblasts
(PT1–PT4) was estimated by culture experiments in 10% FBS SM (white
symbols), in 2% FBS SM (black symbols), and upon serum deprivation
for 48 hour, followed by culture in 10% FBS SM (grey symbols) by
comparing the number of viable cells at 0 hours and at 72 hours of
culture, using CellTiter-GloH Luminescent Cell Viability Assay (Promega).
The short dash line indicates the mean value of cell cycle length of
controls in all growth conditions analyzed, while the dotted lines
represent the mean value 6 one SD.
doi:10.1371/journal.pone.0019081.g004
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PLoS ONE | www.plosone.org 9 April 2011 | Volume 6 | Issue 4 | e19081early organ failure and death [9]. Whether the fibrotic damage is a
direct result of mutations in the ALMS1 gene or, alternatively, a
secondary response to cellular insult due to the loss of ALMS1
function is unknown. However, while hepatic and renal fibrosis
could possibly be explained by the metabolic alterations present in
ALMS patients, such as obesity and type 2 diabetes, it is difficult to
identify a trigger insult causing fibrosis in heart, lung, bladder,
testis and ovary.
Fibrosis is often considered a fibroproliferative disorder in which
the uncontrolled proliferation of activated fibroblasts and the
excessive production of ECM resulted in a functional impairment
of affected organs [11].
We did not observe an enhanced proliferative capacity in ALMS
fibroblasts. On the contrary, ALMS1 mutations in the majority of
our patients are associated with an increase in cell cycle length and
in all patients with a down-regulation of genes directly involved in
cell cycle progression, replication and centrosome-kinetocore
assembly. Fibroblasts obtained from PT4 displayed a normal cell
cyclelengthanditisnoteworthythat onlyPT4 carriedamutationin
exon 16 of ALMS1, thus he could preserve some ALMS function in
hemizygosity. Additional studies regarding the different disease-
causing variants will help us to gain a better understanding of the
phenotypic variability observed among ALMS patients.
The localization of ALMS1 to centrosomes and ciliary basal
bodies [4,6] suggests a role in the regulation of cell cycle
progression. Primary cilia are regarded as postmitotic structures
of quiescent cells [21] and recently were proposed to be involved
in the control of cellular growth. ALMS overlaps clinical
phenotypes of other ciliopathies, as Barbet-Biedl Syndrome
(BBS), and a role for BBS proteins in microtubule organization
and cell cycle progression has been hypothesized [22]. The
increased doubling time we observed in the majority of ALMS
fibroblasts is the first evidence which links ALMS1 function to the
regulation of cell cycle progression.
Figure 5. ALMS fibroblasts are resistant to cell death induced by apoptotic stimuli. (a) Fibroblasts of healthy controls and ALMS patients
were stimulated with thapsigargin (THAP, 100 nM for 48 hours), C2-ceramide (C2-C, 100 mM for 24 hours), cycloheximide (CX, 100 mg/ml for
24 hours), staurosporine (STP, 100 nM for 48 hours) and TNF-a (100 ng/ml for 48 hours) in 10% FBS SM. The % of viable cells was determined by MTT
assay and shown as mean values 6 SEM with respect to unstimulated cells (2) indicated as 100%. *P,0.05, ***P,0.001 cell viability of ALMS
fibroblasts versus controls. (b) Control (C1) and ALMS fibroblast (PT4) were treated with THAP (100 nM for 48 hours), stained with PI and analyzed by
flow cytometry. Results are presented as histograms of cell cycle phase distribution and the reported % represents the increase in sub-G1/G0
population (M1 region). (c) Control (C1) and ALMS fibroblast (PT1) were grown on glass coverslips and stimulated with CX (100 mg/ml for 24 hours)
and THAP (100 nM for 48 hours). Cells were fixed and stained for fluorescence in situ DNA end-labelling (TUNEL) (green stain); nuclei were counter-
stained with DAPI (blue stain) (magnification=206). (d) Control (C1) and ALMS fibroblast (PT1) were treated with THAP (100 nM for 48 and 72 hours).
Cells were labelled by TUNEL and PI and analyzed by flow cytometry. Each cytogram shows the TUNEL positivity (ordinate) with respect to DNA
content (abscissa), upon 48 and 72 hours of THAP-treatment, respectively. A representative control and patient are reported in panel b, c and d; see
also Figure S9 and S10.
doi:10.1371/journal.pone.0019081.g005
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components and regulators associated with increased collagen
synthesis in ALMS fibroblasts. The enhanced intracellular
complexity and the active exocytic dynamic assayed by our
morphological evaluations similarly suggest a constitutive activated
phenotype for dermal ALMS fibroblasts. Furthermore, control
fibroblasts became able to express the same COL1A1 levels as
ALMS fibroblasts only upon 48 hour-treatment with TGF-b.
Additionally, ALMS fibroblasts remain responsive to TGF-b and
the stimulation further increased their COL1A1 expression more
efficiently than controls.
Array experiments showed the mRNA modulation in ALMS
fibroblasts of four out of the six matricellular growth factors belongs
to the CCN family: CTGF, WISP1, CYR61, NOV, all of which
function as adaptor molecules connecting the cell surface to the
ECM. Constitutive over-expression of CTGF has been linked with
systemic sclerosis, keloids and other fibrotic skin disorders [23] and
the up-regulation of WISP1, a WNT signaling pathway target, has
been associated with human idiopathic pulmonary fibrosis [24]. We
also observed a marked up-regulation of POSTN, a protein involved
in proper ECM synthesis [25] and in the hypertrophic response
following myocardial infarction [26]. The strong periostin overex-
pression we observed together with the risk described for developing
cardiomyopathy in ALMS patients [9] is particularly suggestive of a
role of periostin in cardiac remodeling in ALMS.
Taken together all these observations show that ECM
deposition is a dominant pathological mechanism of ALMS
fibrosis, is constitutively present in mutated fibroblasts, and could
be enhanced by the presence of a profibrotic environment.
The 3D-culture experiments showed that ALMS fibroblasts
display an inability to migrate into the inner spaces of the scaffold,
appearing strongly anchored to adjacent cells. This result is in
agreement with expression data indicating the up-regulation of
genes involved in focal adhesion structures and suggesting a closer
cell-matrix association. Furthermore, our morphological analysis
showed the presence of cytoskeletal structures preferentially lined
up to the nuclear polarity in ALMS fibroblasts compared to
controls. The migration and the orientation of fibroblasts with
respect to the collagen fibers are both essential steps in normal
tissue repair [13,27]. Thus, the lack of ALMS1 function could alter
the cell polarity and the efficient migration contributing to the
generation of fibrosis.
Resistance to apoptosis has been described in fibroblasts isolated
from fibrotic lesions in patients with pulmonary fibrosis [28] or
with keloids [15]. Our microarray analysis suggests that ALMS1-
mutated fibroblasts could possess some alterations in genes
involved in the apoptotic pathway regulation and partially in the
control of stress-induced cell death. Moreover the treatment with
some apoptotic inductors (THAP, C2-C and CX) is more efficient
in controls than in ALMS fibroblasts, indicating that a specific
apoptotic pathway could be altered in mutated cells. These results
suggest that ALMS fibroblasts display a ‘‘prosurvival phenotype’’
that could play a role in the generation of fibrosis interfering with
the control of the fibroproliferative response.
Dermal ALMS fibroblasts display a constitutive activation of an
a-SMA-myofibroblast like phenotype, indicating autonomous,
signal-independent alterations, directly due to mutations in ALMS1
gene. They divide more slowly and are less susceptible to
Figure 6. Model of fibrosis in Alstro ¨m Syndrome. Fibroblasts carrying ALMS1 mutations display an elongated shape, proliferate slowly, but are
still responsive to pro-fibrotic factors and resistant to cell-death stimuli, suggesting that their proliferation is not controlled by apoptosis. ALMS1
mutated fibroblasts persist, continue to proliferate and to synthesize and secrete high levels of ECM, responsible for progressively remodeling and
destroying normal tissue architecture, resulting in fibrosis. The microenvironment could be characterized by an excess of mediators enhancing a
cellular pro-fibrotic phenotype, that together with inflammatory reactions could stimulate the fibrosis in an autocrine loop.
doi:10.1371/journal.pone.0019081.g006
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and produce an excess of ECM, resulting in fibrosis. Moreover
ALMS fibroblasts keep themselves responsive to profibrotic
inductors contributing to the perpetuation of fibrosis (Figure 6).
In conclusion, we show that fibrosis in ALMS is a primary
defect due to ALMS1 mutations leading to the fibrotic phenotype
described in ALMS patients. Moreover, ALMS1 is a multifunc-
tional protein, with roles in cell cycle progression, migration,
apoptosis and ECM production. Further studies investigating the
involvement of ALMS1 in both intra- and extra-cellular events will
be helpful in unraveling the pathophysiology of ALMS to facilitate
the identification of key therapeutic targets.
Supporting Information
Figure S1 Age-associated genes expression and relative
telomere lengths in control and ALMS fibroblasts. (a)
p66
Shc/SHC1 p66 isoform, SIRT1, SIRT5, c-Myc/MYC and p21/
CDKN1A transcripts were quantified by qPCR and normalized to
HMBS mRNA content in control (black bars) and ALMS
fibroblasts (white bars). Results are reported as mean values 6
SD and are expressed as fold change with respect to controls,
arbitrarily set as 1 for each transcript. (b) Telomere lengths
estimated by real-time PCR (T/S value) in control (black bars) and
ALMS fibroblasts (white bars) are reported as mean values 6 SD.
Fibroblasts were analyzed at the same passages in culture (XII–
XIV); no correlation was found between T/S value, the age of
subjects or the number of passages.
(DOC)
Figure S2 Senescence-associated b-galactosidase activi-
ty of control and ALMS fibroblasts. Control (C1, C2, C3)
and ALMS fibroblasts (PT1, PT2, PT3, PT4) at similar passages in
culture (XII–XIV) were fixed and stained for b-galactosidase
activity at pH 6.0. 293 cells (XXX passage) and 293 cells
transiently transfected with plasmid encoding for b-gal were used
as positive controls. Magnification: 326.
(DOC)
Figure S3 Size and shape of ALMS fibroblasts. (a)
Fibroblasts of healthy controls (C1, C2) and ALMS patients
(PT1, PT2, PT4) were grown on standard tissue culture (2D
cultures) coverslips and stained with hematoxylin-eosin (magnifi-
cation 206). (b) ALMS fibroblasts were compared with controls by
flow cytometric analysis and the resulting forward (FSC-H) and
side light scatter (SSC-H) mean intensity values and SEM are
shown for each subject. The statistical analysis of SSC-H was
carried out with the Kolmogorov-Smirnov test which is significant
(value .8) for PT1 and PT3 vs C1=26.5 and also for PT1 and
PT3 vs C3=11.3.
(DOC)
Figure S4 Motility assay and ultrastructural evaluation
of ALMS fibroblasts. (a) Fibroblasts of healthy controls (C1,
C3) and (b) ALMS patients (PT1, PT3) were cultured in HYAFF-
11
TM scaffolds (3D-cultures) and stained with hematoxylin-eosin
(magnification 56). Transmission electron microscopy was
performed in healthy controls (C1, C3) (c–d) and ALMS
fibroblasts (PT1, PT3, PT4) (e–f) on 3D-cultured cells. Control
fibroblasts showed a normal phenotype, with cytoplasm rich in
perpendicular oriented microfilaments (c, rings) and the presence
of some pinocytic vesicles (d, arrows). In contrast, in ALMS
fibroblasts microfilaments (e, rings) were arranged in a unique
direction, parallel to the long axis of the cells. A large number of
exocytic vesicles (f, arrows and ring) suggest an active secretion.
Magnification: c=400006; d(C1)=250006; d(C3)30000; e=
300006; f=25000.
(DOC)
Figure S5 Relative mRNA levels of collagens in ALMS
fibroblasts. COL1A1, COL3A1, COL4A1, COL5A1, COL5A2,
COL8A1, COL11A1, COL12A1, COL15A1 transcriptswere quantified
byqPCRinALMS fibroblasts (ALMS)and controls(CONTROLS).
Results are reported as threshold cycle (Ct) for each specific qPCR
reaction and are expressed as mean values 6 SEM.
(DOC)
Figure S6 Increased mRNA expression of ECM compo-
nents in ALMS fibroblasts. (a) POSTN, (b) ACTA2, (c) COL1A1,
(d) COL3A1,( e )COL4A1, (f) COL5A1, (g) COL5A2, (h) COL8A1, (i)
COL11A1, (l)COL12A1, (m)COL15A1transcripts were quantifiedby
qPCR and normalized to HMBS mRNA content in control (black
bars) and ALMS fibroblasts (white bars). Results are reported
as mean values 6 SEM arbitrary units (AU) ratio. *P,0.05,
** P,0.01, *** P,0.001 ALMS fibroblasts versus controls.
(DOC)
Figure S7 Pro-fibrotic factors increase COL1A1 expres-
sion and cellular proliferation in ALMS fibroblasts. (a)
Fibroblasts of healthy controls and ALMS patients were stimulated
with TGF-b (10 ng/ml) in 5% FBS SM. COL1A1 mRNA was
quantified by qPCR and normalized to HMBS mRNA content.
Results are given as fold increase versus unstimulated controls
(0 h), set as 1, and presented as mean values 6 SEM. **P,0.01
stimulated (48 h) versus unstimulated (0 h) ALMS fibroblasts; #
P,0.05 stimulated ALMS fibroblasts versus stimulated control
fibroblasts (48 h). (b) The effect of treatment with TGF-b (10 ng/
ml), CTGF (100 ng/ml) and FGF2 (10 ng/ml) in 2% FBS SM for
72 hours on cellular proliferation was evaluated in ALMS and
control fibroblasts using the CellTiter-GloH Luminescent Cell
Viability Assay (Promega). Results are given as % of viable cells
with respect to unstimulated cells, indicated as 100%. ***P,0.001
stimulated with FGF2 versus unstimulated ALMS fibroblasts.
(DOC)
Figure S8 ALMS fibroblasts are resistant to cell death
induced by apoptotic stimuli. Fibroblasts of healthy controls
(black bars) and ALMS patients (white bars) were stimulated with
(a) thapsigargin (100 nM for 48 hours), (b) C2-ceramide (100 mM
for 24 hours), (c) cycloheximide (100 mg/ml for 24 hours), (d)
staurosporine (100 nM for 48 hours) and TNF-a (100 ng/ml for
48 hours) in 10% FBS SM. The % of viable cells was determined
by MTT assay and shown as mean values 6 SEM with respect to
unstimulated cells indicated as 100%. *P,0.05, ***P,0.001 cell
viability of ALMS fibroblasts versus controls.
(DOC)
Figure S9 ALMS fibroblasts are resistant to cell death
induced by apoptotic stimuli. (a) Control (C3) and ALMS (PT2)
fibroblasts were treated with THAP (100 nM for 48 hours), stained
with PI and analyzed by flow cytometry. Results are presented as
histograms of cell cycle phase distribution and the reported %
represents the increase in sub-G1/G0 population (M1 region). (b)
Control (C2) and ALMS (PT3) fibroblasts were treated with THAP
(100 nM for 48 and 72 hours).Cells werelabelled by TUNELand PI
and analyzed by flow cytometry. Each cytogram shows the TUNEL
positivity (ordinate) with respect to DNA content (abscissa), upon 48
and 72 hours of THAP-treatment respectively.
(DOC)
Figure S10 ALMS fibroblasts are resistant to apoptosis.
Control (C2, C3) and ALMS fibroblasts (PT2, PT3, PT4) were
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PLoS ONE | www.plosone.org 12 April 2011 | Volume 6 | Issue 4 | e19081grown on glass coverslips and stimulated with CX (100 mg/ml for
24 hours) and THAP (100 nM for 48 hours). Cells were fixed and
stained for fluorescence in situ DNA end-labelling (TUNEL) (green
stain); nuclei were counter-stained with DAPI (blue stain) or with
PI (red stain). Magnification=206.
(DOC)
Table S1 Primer sequences and conditions used in
qPCR. POSTN=periostin, ACTA=actin, alpha-2, smooth mus-
cle, aorta, COL1A1=collagen, type I, alpha 1; COL3A1=collagen,
type III, alpha 1; COL4A1=collagen, type IV, alpha 1;
COL5A1=collagen, type V, alpha 1; COL5A2=collagen, type V,
alpha 2; COL8A1=collagen, type VIII, alpha 1; COL11A1=colla-
gen, type XI, alpha 1; COL12A1=collagen, type XII, alpha 1;
COL15A1=collagen, type XV, alpha 1; HMBS=hydroxymethyl-
bilane synthase; CDKN1A=cyclin-dependent kinase inhibitor 1A
(p21, Cip1); MYC=v-myc myelocytomatosis viral oncogene
homolog (avian); SHC1 (p66 isoform)=SHC (Src homology 2
domain containing) transforming protein 1; SIRT1=sirtuin 1;
SIRT5=sirtuin 5.
(DOC)
Table S2 Gene expression modulation in ALMS versus
control fibroblasts. Differentially expressed genes, identified by
microarray experiments, were analyzed and grouped by functions.
Tables reported only informative genes for each class. The
columns show Gene Symbol, Gene Bank, Unigene accession
number, gene description and the relative fold change. Each
reported gene passed SAM statistic.
(DOC)
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